DNA vaccine could help hepatitis b patients stop daily pills

NCT ID NCT00536627

Completed Disease control Sponsor: French National Agency for Research on AIDS and Viral Hepatitis Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a DNA vaccine can help people with chronic hepatitis B control the virus after they stop taking standard antiviral drugs. The vaccine aims to boost the immune system to delay the virus from becoming active again. The trial involves 70 adults who have undetectable virus levels and are currently on treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DNA vaccine pCMVS2.S
What this could lead to: If successful, this could offer a way to control hepatitis B without lifelong medication, potentially reducing the need for daily antiviral pills.
What could go wrong: This is an early-phase trial with only 70 participants, so results may not apply widely. The vaccine may not prevent viral reactivation, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

FONTAINE Hélène

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.